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leasing hormone (CRH) suppresses
immunological functions via stimulation
of the pituitary-adrenal axis, but is also
found in peripheral tissues. Peripheral
proinflammatory activity of CRH is
suggested by increased tissue concen-
trations in arthritis and in vitro inmmuno-
stimulatory effects. This study evaluated
intestinal CRH concentrations, immuno-
localisation, and synthesis in chronic en-
terocolitis and investigated in vitro
responsiveness of lamina propria mono-
nuclear cells to CRH.
Methods-Chronic granulomatous en-
terocolitis was induced by intramural
injection of peptidoglycan-polysaccharide
polymers in the ileocaecal region of Lewis
rats. CRH protein was measured in caecal
specimens by immunohistochemistry and
radioinmunoassay and caecal CRRH
mRNA expression was analysed by reverse
transcriptase polymerase chain reaction.
Results-In the chronically inflamed
caecum abundant immunoreactive CRH
was found in inflammatory cells, mesen-
chymal cells, as well as in myenteric plexi.
In contrast, only a few CRH containing
cells were detected in normal and HSA
injected control caecums. Moreover,
caecal CRH protein levels were increased
during chronic enterocolitis. Local CRH
synthesis as indicated bymRNA expression
was considerably increased in chronic en-
terocolitis whereas it was undetectable or
low in uninflamed caecum. In addition,
CRH stimulated in vitro proliferation of
lamina propria mononuclear cells and
inhibited mitogen induced proliferation.
Conclusion-Increased CRH protein and
mRNA expression in chronic enterocolitis
and responsiveness of intestinal mono-
nuclear cells to CRH indicate an immuno-
modulatory role for locally produced CRH
in intestinal inflammation.
(Gut 1996; 39: 385-392)
Keywords: corticotropin releasing hormone,
experimental enterocolitis, Lewis rats.
Regulation of immune reactivity to mucosal or
systemic noxious stimuli without inducing
destructive chronic inflammation requires
balanced interaction between the nervous,
endocrine, and immune systems. The immune
system shares bi-directional communication
pathways with both the nervous and endocrine
networks. 1-3 For example, peripheral and
mucosal lymphoid organs have direct neuro-
peptidergic innervation.4 5 Not only can
immune cells be found in intimate association
with nerve fibres,6 they also have specific high-
affinity receptors for neuropeptides and hor-
mones.7 Furthermore, hormones and neuro-
peptides endogenous to the gastrointestinal
tract modulate the activity of immune cells
isolated from gut associated lymphoid tissues
and the intestinal lamina propria.8 9 A variety
of neuropeptides can be synthesised by
immune cells suggesting that neuropeptides
have autocrine/paracrine actions on immune
cells or that the immune system shares
functional homology with the neuroendocrine
system.3 l Together, these findings indicate
that neuropeptides and hormones can regulate
the activity ofimmune cells in endocrine, para-
crine, and possibly autocrine fashions similar
to immunoregulatory activities of cytokines.
Local production of corticotropin releasing
hormone (CRH) has been associated with
peripheral inflammation' 1-3 suggesting that this
neuropeptide may have a proinflammatory role
when produced outside the brain. This is in
sharp contrast with its well known immuno-
suppressive role as the key regulator of the
hypothalamus-pituitary-adrenal axis. At present
it is firmly established that the production of
CRH is not confined to the hypothalamus.
CRH has been demonstrated in the normal
spinal cord, lung, liver, spleen, stomach,
pancreas, ovaries, placenta, endometrium, and
intestine with differential distribution among
mammalian species.1421 More importantly, in
vitro studies almost unequivocally point to an
immunostimulatory effect of CRH. CRH
stimulates cytokine secretion,22-24 increases the
expression of interleukin 2 receptors on T
cells,25 increases the FMLP induced production
of reactive oxygen metabolites by macro-
phages,26 stimulates both spontaneous and
ConA induced splenocyte proliferation,25 27
(van Tol unpublished observations), and stimu-
lates natural killer cell activity.28
In contrast, not much is known about the
role of local production of CRH in the patho-
genesis of tissue inflammation although
increased CRH protein or mRNA expression,
or both, are found in human arthritis and rat
models of bacterial cell wall induced arthritis
and carrageenin induced granulomatous
exudative inflammation. 11-13 Direct evidence
for the pivotal peripheral role of CRH in
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experimental inflammation came from the
carrageenin model in which systemic immuno-
neutralisation of CRH resulted in marked
suppression of inflammation."
In this study we investigated the presence
and local production of CRH in a model of
chronic enterocolitis. Subserosal intramural
injection of poorly degradable, purified
peptidoglycan-polysaccharide from group A
Streptococcus pyogenes (PG-APS) in the caecum
and distal ileum induces biphasic inflammation
in genetically susceptible Lewis rats.29 Granu-
lomatous enterocolitis with associated arthritis,
hepatic granulomas, anaemia, and leucocytosis
spontaneously develops approximately two
weeks after a single injection of PG-APS.29 30
Transmural granulomatous inflammation with
extensive fibrosis is characteristic for the
chronic phase of enterocolitis that persists for
at least 16 weeks in this model.
In this and other experimental models of
inflammation Lewis rats have been shown to be
a highly susceptible strain.29-3' Part of this
genetic susceptibility in Lewis rats underlying
the development of exaggerated inflammation
may involve a blunted hypothalamic CRH
response to bacterial cell wall products, cyto-
kines, and neurotransmitters.31"
Here we hypothesise that Lewis rats have
increased peripheral CRH production asso-
ciated with chronic inflammation, and that
local proinflammatory effects of CRH contri-
bute to the development or perpetuation of
chronic intestinal inflammation, or both, in a
susceptible host.
Methods
Bacterial cell wall preparation
Sterile PG-APS polymers with the molecular
weight of 5X 1 o6 kDa to 5X 1 o8 kDa were
prepared from group A, type 3 strain D58
Streptococcus pyogenes as described previously34
and provided by Dr J Schwab and R Brown,
Department of Immunology and Micro-
biology, University of North Carolina at
Chapel Hill. The preparation was sonicated to
disperse aggregates immediately before use and
the final concentration was calculated based on
rhamnose content.35
Induction of enterocolitis
Female, inbred specific pathogen free (SPF)
Lewis rats (140-160 g) were obtained from
Charles Rivers Breeding Laboratories
(Raleigh, NC) and kept in a SPF facility with
free access to food and water. All experiments
were performed in compliance with the criteria
outlined by the University of North Carolina
Institutional Animal Care and Use Committee.
Animals were anaesthetised with 1.3 ml/kg
body weight Innovar (Pitman-Moore Co,
Washington Crossing, NJ), the intestines were
exposed by aseptic laparotomy and subsero-
sally injected with PG-APS (12.5 ,ug
rhamnose/g body weight) or the same dose of
human serum albumin (HSA, Baxter Health
Care) as described previously.29 A total volume
of 0.45 ml was divided over seven injection
sites including the junction of the mesentery
and the distal ileum (two injections X0.05 ml),
two distal ileal Peyers' patches (2X005 ml),
the caecal tip (lymphoid aggregate, 0.05 ml),
and the mid and upper caecum (two sites X0 1
ml). Rats in the acute inflammation group were
killed 48 hours after injections whereas rats in
the chronic inflammation group were killed 29,
33, or 85 days after injections. All animals were
killed by overdose inhalation of CO2. Gross
inflammation was scored by a single blinded
observer according to criteria developed and
validated for this model.29 Values of 0-4 were
assigned to the number of caecal nodules,
contraction of mesentery, number and severity
of adhesions, and caecal wall thickening, with
a maximal possible summed gross gut score
(GGS) of 16.
Tissue collection and processing
Caecal tissue samples were snap frozen in
liquid nitrogen and stored at -80°C for
isolation of RNA and protein. The caecal tip
was oriented in a plastic container with OCT
(Miles Inc, Elkhart, IN), snap frozen in
isopentane, and stored at -80°C for immuno-
histochemistry studies. Total RNA was iso-
lated from samples of caecal tissue from PG-
APS, HSA injected, and normal Lewis rats
using a standard procedure.29 RNA concen-
tration and purity was quantified by ab-
sorbance at 260 nm and A260/280 ratios. The
integrity of RNA was verified by electro-
phoresis of samples in 1.4% agarose gels
containing ethidium bromide.
Immunohistochemistry
Indirect immunohistochemical staining for rat
CRH was done using the avidin-biotin peroxi-
dase complex (ABC) kit (Vectastain, Vector
Lab, Burlingame, CA). Sections of brain from
a longterm adrenalectomised Lewis rat were
used as controls because immunostaining of
CRH is increased in the brain due to lack of
corticosteroid feedback inhibition. Ten ,um
frozen sections were cut from the brain of the
adrenalectomised rat and from fresh frozen
caecal tips collected from PG-APS or HSA
injected or normal Lewis rats. Sections were
post-fixed in 4% paraformaldehyde with 10%
sucrose for five minutes and washed in
phosphate buffered saline (PBS). All incu-
bations were performed at room temperature
unless otherwise stated. Sections were treated
with methanol and 0.6% H202 for 45 minutes
to exhaust endogenous peroxidase activity,
incubated with 2% normal goat blocking
serum in PBS for 10 minutes, then incubated
overnight with either the primary rabbit antirat
CRH antiserum (1:500-1:1000 dilutions,
Peninsula Lab, Belmont, CA), normal rabbit
serum, rabbit IgG, or 2% normal goat serum
at 4°C. The sections were washed in PBS, and
incubated with 2% normal goat serum
blocking solution for 10 minutes, followed
by incubation with biotinylated goat anti-
rabbit IgG (1:400 dilution, Organon Teknika,
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Durham, NC) for 45 minutes, washed in PBS,
and incubated with the A and B components
(1:400) of the Vectastain kit for 45 minutes.
Coloured precipitation product was developed
by immersing sections in 0.05 M TRIS-HCL
buffer pH 7.4 containing 0-075% 3,3 diamino-
benzidine tetrahydrochloride (DAB, Aldrich
Chemical, Milwaukee, Wi) and 0-02% H202.
After washing in TRIS buffer and PBS, the
staining was intensified with evaporating OS04
(2% in dH2O) for five minutes, washed in PBS,
counterstained with 0.050/o toluidine blue in
30% ethyl alcohol, dehydrated through graded
alcohols and xylene, mounted with Permount
(Fisher Scientific, Pittsburgh, PA), and cover
slipped.
Radioimmunoassay (RIA) and non-collagen
protein determinations
For extraction of immunoreactive CRH
(irCRH), total protein, and collagen the tissues
were homogenised in 1 ml of 0 1 N acetic acid
for 30 seconds using a Tissuemizer. The homo-
genates were boiled for five minutes, cooled on
ice for five minutes followed by centrifugation
for 10 minutes at 2000Xg. The supernatants
were collected and stored at -20°C. CRH
concentrations were determined using a
specific radioimmunoassay for rat/human
CRH (Peninsula Lab, Belmont, CA). Total
protein concentrations in the supernatants
were determined using a microprotein assay
(Sigma, St Louis, MO).
Collagen measurements
An 100 ,u aliquot ofthe tissue homogenate was
lyophilised and subsequently hydrolysed with
6N HCL in vacuo under N2 at 11 0°C for 22
hours. The hydrolysate was dried by a speed
vacuum concentrator, dissolved in distilled
water, filtered with 0.22 ,um membrane, and
subjected to amino acid analysis using a Varian
5500 HPLC system.36 The relative amount of
collagen in the total protein fraction was
determined using a value of 100 residues of
hydroxyproline per 1000 for a typical fibrillar
collagen standard.36
RT-PCR
For the reverse transcriptase polymerase chain
reaction (RT-PCR) analysis of CRH mRNA,
1 ,ug of total RNA isolated from intestinal
tissues and brain controls was reverse tran-
scribed to cDNA using random hexamers in a
reaction volume of 50 ,ul containing 200 units
of Superscript Reverse Transcriptase RNase
H- (Gibco BRL, Gaithersburg, MD), 50 mM
TRIS-HCL (Gibco), 75 mM KCL (Gibco), 3
mM MgCL2 (Gibco), 10 mM DTT (Gibco),
1 mM dNTP (Perkin Elmer/Applied Bio-
systems, Foster City, CA), 1 ,uM random
hexamers (Perkin Elmer), and 0.5 Units/,lp
RNase inhibitor (Perkin Elmer). The reaction
mixture was incubated for 45 minutes at 45°C,
boiled for five minutes to stop the reaction,
cooled on ice for three minutes, and stored at
-20°C. All PCR reactions were done in a 50
,lI reaction volume with 1 ,u of the first strand
cDNA and 50 mM KCl, 20 mM TRIS-HCL,
2.5 ,uM MgCL2, 0 1-0 5 mM dNTPs,
0. 1-0 25 mM of each antisense and sense
primer, and 1.5-2.5 U of Taq polymerase
(Perkin Elmer). The primers used for rat CRH
were sense 5' CAAGTACGTTGAGAAACT-
GAAG and antisense 5' CCGAGCAGCGGG-
ACTTCTGT for the first amplification and
the same sense primer with antisense 5' GG-
GCTGCTCCGGTTGCAAG for the semi-
nested primer second amplification run. For
the nested primer amplification, 1 gl of the first
PCR product obtained after 35 cycles was
diluted 1:250 and used as a template in a fresh
reaction mix for a second amplification of 32
cycles. For rat 3-actin12 sense 5' ACCACAGC-
TGAGAGGGAAATCG and antisense 5' AG-
AGGTCT-ITACGGATGTCAACG primers
were used for 25-30 cycles amplification. All
primers were constructed to span an intron to
enable assessment of contaminating genomic
DNA. Conditions for amplification of rat CRH
were denaturation at 95°C for five minutes,
and amplification cycles, 94°C for 45 seconds,
58°C for one minute, 72°C for 1.5 minutes,
and for rat ,B-actin 94°C for 45 seconds, 60°C
for one minute, and 72°C for 1.5 minutes. Rat
brain cDNA was used as a positive control and
to optimise amplification conditions for CRH
mRNA. Amplifications without cDNA were
run as negative controls. The PCR products
were analysed on a 1-5% agarose TAE gel
containing ethidium bromide. The specificity
of the amplification product was confirmed by
size and by obtaining fragments of predicted
size (245 and 62 bp) after digestion with
restriction enzyme BamHl (Boehringer
Mannheim).
Lamina propria mononuclear cell (LPMC)
isolation and in vitro stimulation
LPMC were isolated from ileal tissue from
normal Lewis rats. Tissue was washed in
calcium and magnesium free Hank's balanced
salt solution (CMF-HBSS) with antibiotics.
The tissue was cut longitudinally, washed, cut
into smaller pieces, and incubated in CMF-
HBSS with 10 mM DTT (Sigma) and anti-
biotics for 20 minutes at room temperature.
After washing, the tissue was transferred to
prewarmed CMF-HBSS with 0.8 mM ethy-
lenediamine tetraacetic acid (Fischer Scien-
tific, Pittsburgh PA) and additives for four to
five sequential incubations. After epithelium
depletion the tissue pieces were cut smaller and
incubated twice for one hour in RPMI with
10% FCS, antibiotics, and Dispase grade I
(0.08 mg/ml, Boehringer Mannheim) and
DNase grade II (0.075 mg/ml, Boehringer
Mannheim) at 37°C on a shaking table. After
enzymatic digestion the supernatants were
filtered through a mesh (Nitex, Tetko Inc,
Elmsford, NY), washed, and mononuclear
cells were isolated by density gradient centri-
fugation (Histopaque, 1.083 g/1, Sigma). Then
the cells were washed, counted, and cultured
at 2X 106 cells/ml in 200 gl of RPMI supple-
mented with 10% FCS, antibiotics and
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synthetic CRH 1-41 (Sigma) or 025 ,ug/well
ConA (Sigma), or both, in 96 well microtitre
plates. The plates were incubated in 5% CO2
at 37°C for 72 hours and cells were pulse
labelled with 50 ,uCi/well 3[H]-thymidine
(Amersham, Arlington Heights, IL) 18 hours
before harvesting and proliferation was
measured by liquid scintillation counting.
Statistics
The data are presented as mean (SEM).
Groups were compared using the unpaired two
tailed Student's t test. In the proliferation
studies dose dependency of the CRH incu-
bations was analysed by multiple regression
analysis followed by the Wilcoxon's signed




To confirmn induction of chronic intestinal
inflammation, the gross gut score (GGS) for
enterocolitis was determined. The score, which
includes adhesions, mesenteric contractions,
caecal serosal nodules, and caecal wall
thickening, was significantly increased during
the acute phase after two days (6.7 (0.4) (PG-
APS) v 0.3 (0.3) (HSA), p=00001). This
increase in the GGS was even more pro-
nounced during the chronic phases of inflam-
mation, as shown at 26 days (8.7 (06) (PG-
APS) v 06 (0.3) (HSA), p=0O0001) and 29
days (9.3 (1.6) (PG-APS) v 1.3 (0.7) (HSA),
p=0O0012). The HSA injected control animals
showed no signs of active intestinal inflam-
mation at all evaluated time points.
Immunohistochemistry
Specificity of the anti-CRH serum was tested
on sections of the hypothalamus from an
adrenalectomised rat. Strong immunoreactive
CRH staining was visible in the external layer
of the median eminence at the base of the third
ventricle (data not shown). Incubations with
normal rabbit serum, purified rabbit IgG, as
well as normal goat serum were found to be
uniformly negative.
The histological appearance of chronic
colitis in the caecal tip consists of active
granulomatous inflammation in a transmural
distribution with extensive fibrosis and evi-
dence of an acute inflammatory component;
the submucosa is particularly involved. Abun-
dant presence ofCRH immunoreactive cells in
the inflamed caecum was observed in chronic
enterocolitis 85 days after PG-APS injection
(Fig 1A). Anti-CRH immunostaining of caecal
tip sections of normal Lewis caecum and of
HSA injected control animals at 33 days (Fig
1 B), showed a pattern of rarely scattered CRH
immunoreactive cells in the submucosa, which
might be of neuronal origin and weak staining
of plexi in the external muscle layer. No
staining was seen in crypt epithelial or neuro-
endocrine cells. During the chronic phase of
inflammation several different cell types were
found to contain irCRH. Similar to what was
found in the acutely inflamed caecal tissues
(two days, data not shown), CRH im-
munoreactivity was seen in inflammatory cells
with a predominant macrophage-like appear-
ance in the chronic phase of PG-APS induced
enterocolitis (Fig 1 C). CRH was also detected
within the myenteric plexi, which appeared to
be hyperplastic (Fig 1D). In addition, mesen-
chymal cells lining the periphery ofgranulomas
were positive for irCRH (Fig 1E). Control
incubations ofthe chronically inflamed caecum
with normal rabbit serum, purified rabbit IgG,
normal goat serum (Fig 1F) as well as serial
dilutions of the primary CRH antiserum
confirmed specificity of the immunostaining
for CRH in gut tissue and the absence of
endogenous peroxidase activity.
Tissue concentrations ofCRH by
radioimmunoassay
Whole caecal tissue CRH concentrations were
significantly increased in the chronic phase of
inflammation in PG-APS-injected rats as
detected by specific RIA (Fig 2A). Smaller
amounts of irCRH could also be detected in
caecal tissues ofHSA injected control animals.
Because the increase in irCRH in chronically
inflamed caecum is accompanied by a rela-
tively large increase in the total protein content
per gram ofwet tissue due to the inflammation,
CRH contents were normalised based on the
amount of protein extracted (Fig 2B). In this
model of granulomatous enterocolitis however,
there is abundant deposition of collagen in the
chronic phase of inflammation as revealed by
Masson's trichrome staining.30 Based on amino
acid analysis it was also determined that the
collagen fraction comprised a significantly
larger proportion of the total caecal protein
content in the PG-APS injected group com-
pared with HSA injected control animals (25%
v 8%, p<005). Adjusting the tissue concen-
tration of CRH based on non-collagenous
protein demonstrated a 2-2-fold increase in the
mean concentration of irCRH in chronically
inflamed tissues compared with the HSA
injected control caecal tissue (Fig 2C).
RT-PCR analysis
We were unable to detect CRH mRNA in
caecal tissue samples from PG-APS or HSA
injected Lewis rats by northern blot hybrid-
isation using a cDNA probe (data not shown).
However, we were able to detect CRH mRNA,
which is constitutively expressed in the hypo-
thalamus, in normal Lewis rat brain samples by
this method. Therefore we used RT-PCR to
detect the relatively low transcript levels of
intestinal CRH mRNA. The RT-PCR amplifi-
cation conditions using a semi-nested primer
amplification technique were optimised using
the normal Lewis rat brain as a positive control
and were used to evaluate CRH mRNA
expression during different phases of chronic
inflammation in the caecum. This semi-
quantitative assessment of CRH mRNA
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Figure 1: Immunohistochemical stainingfor CRH in caecal tissues derivedfrom Lewis rats after intramural inuectionls of
PG-APS, 85 days (A, C-F) or HSA, 33 days (B). CRH immunoreactivity is visualised in inflammatory and
mesenchymal cells in the submucosa, particularly surrounding a granuloma (arrow) and in nervous tissue between the
hypertrophic external muscle layers (arrowhead) (A, original magnification X 40). Only a few CRH immunoreactive cells
(arrows), possibly of nervous tissue origin, arefound in control tissues 33 days after HSA injection (B, original
magnification X 100). CRH containing macrophage-like cells arefound in focal areas ofmononuclear cellular infiltrate
during chronic inflammation (C, original magnification x 400). CRH immunoreactivity is also present within the
myenteric plexus (D, original magnification X 200) and in mesenchymal cells comprising the peripheral rim of a submucosal
granuloma (E, original magnification X 100). Negative staining was obtained in control incubations of the same PG-APS
induced chronically inflamed caecal specimen using normal goat serum (F, original magnification X 100).
expression was done by normalising for consti-
tutive 1-actin mRNA levels in each individual
sample. Although this does not yield exact data
on the fold increase of mRNA message it
clearly showed high CRH mRNA expression at
all time points during chronic caecal inflam-
mation at 29, 33, and 85 days after PG-APS
injection (Fig 3). In contrast, the CRH mRNA
message was undetectable or in some cases
very low in uninjected or control HSA injected
caecal tissues compared with the inflamed
tissue samples.
Proliferation studies
CRH stimulated the proliferation of LPMC
isolated from normal Lewis rat ileum in a dose
dependent fashion (Fig 4A). Incubation of the
cells with ConA (0.25 ,ug/well) stimulated pro-
liferation to a similar extent as was obtained
with the higher concentration of CRH in the
non-mitogenic stimulation experiment (Fig
4B). However, co-incubation of ConA stimu-
lated cells with different concentrations of CRH
inhibited proliferation of LPMC (Fig 4B).
Discussion
It is now firmly established that CRH is also
present outside the brain in peripheral tissues
and immune cells. This study shows increased
local CRH synthesis during PG-APS induced
chronic intestinal inflammation. Increased
concentrations of irCRH were detected by
radioimmunoassay in the chronically inflamed
caecum of Lewis rats compared with low
constitutive values in HSA injected control
animals. Tissue CRH concentrations were
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Figure 2: Radioimmunoassay determinations ofCRH tissue concentration in caecal
homogenates 29 days after PG-APS or control HSA injections measured in the extracted
tissue supernatants (A), normalisedfor the total protein content in the extracts (B) as well
as correctedfor the proportion of collagen in the extracted total protein fraction (C).
Significantly increased CRH concentrations were detected in the PG-APS induced





Figure 3: PCR analysis of reverse transcribed RNA isolated
from caecal tissue ofPG-APS orHSA injected and normal
Lewis rats. Primers specific for rat CRH generated a 307 bp
fragment after semi-nested primer amplification. cDNA
transcribedfrom Lewis brain RNA samples and PCR
reaction samples without cDNA added were included as
positive and negative controls respectively. Control
amplification of the samples using primers specific for rat (P
actin generated the predicted 281 bpfragment and
confirmed equal loading. The data have been consistently
reproduced in more than 10 separate assays ofrandomly
selected chronically inflamed and control tissuesfrom rats in















Figure 4: Effect ofsynthetic CRH on proliferation ofLPMC isolatedfrom normal Lewis rat
ileum. Spontaneous (A) or ConA induced (B) proliferation after 72 hours LPMC culture
presented as the mean cpm of 3[H]-thymidine incorporation. Dose dependency ofCRH
induced stimulation ofspontaneous proliferation (A, p=0.018) or inhibition ofConA
stimulated proliferation (B, p=0 019) was analysed by multiple regression with CRH as an
independent variable. n=6, *p<0.05 compared with control media incubation.
measured in total caecal homogenates and do
not accurately reflect local concentrations,
which may reach substantially higher values in
focal areas of inflammation or near nerve
endings. Although local CRH production
cannot be accurately measured, it is quite likely
that some intestinal inflammatory cells are
exposed to CRH concentrations capable of
modulating their activity. The ability of
intestinal immune cells to respond to CRH is
indicated by dose dependent effects on pro-
liferation ofLPMC.
Immunohistochemistry was performed to
determine the cellular source of location of
increased irCRH demonstrated by RIA. Infil-
trating mononuclear cells, (myo)fibroblast-like
cells surrounding granulomas, and myenteric
plexi stained for CRH in the chronically
inflamed caecum in contrast with only sparsely
scattered positive cells in the normal or HSA
injected controls. This staining pattern is very
similar to that described in other models of
experimental inflammation in rats." 12 How-
ever, our findings in the rat intestine do not
match the few reports of CRH in the normal
human gastrointestinal tract. Nieuwenhuijzen
Kruseman et all4 demonstrated CRH in
mucosal cells of the antrum and small intestine
whereas Kawahito et al'9 found that irCRH
colocalised with 5-HT in normal colonic
enterochromaffin cells, and found abundant
CRH protein in colonic lamina propria macro-
phages of patients with active ulcerative
colitis.37 We also found irCRH staining in
macrophage-like cells in the inflamed caecum
but not in normal or inflamed rat colonic
epithelial cells. The reason for these species
differences is unclear.
To establish the relative contributions of
CRH derived from immune cells versus
nervous tissues in PG-APS induced arthritis,
Crofford et al12 treated rats with dexame-
thasone. Discordant effects of treatment on
synovial CRH production and mononuclear
cell infiltration and early increases in CRH
staining prior to cellular infiltration suggested
that the nervous system may contribute to the
increased CRH concentrations in inflamed
synovium. Similarly, CRH production by the
enteric nervous system may contribute to PG-
APS induced chronic enterocolitis. Wolter16
demonstrated that perikarya and nerve fibres in
the myenteric plexus and submucosal nerve
fibres of normal rat duodenum contain CRH.
We found increased CRH staining in neuronal
plexi in the chronically inflamed caecum of
Lewis rats. In addition, neuropeptides can be
produced by enteric glial cells, which secrete
increased amounts of substance P when stimu-
lated by ILL`38 IL1 is also a potent stimulus of
CRH secretion in the brain39 and is
considerably increased during chronic PG-
APS induced enterocolitis.29 Interactions
between cytokines and the enteric nervous
system may be important in the regulation of
CRH secretion and in the perpetuation of
inflammation.
Increased CRH mRNA expression during
different phases of chronic granulomatous
enterocolitis clearly demonstrates local
U
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production rather than transport of preformed
CRH from remote production sites to the
intestine. Crofford et al detected CRH mRNA
in the synovium of a Lewis rat with adjuvant
induced arthritis but results could not be
compared with healthy joints because of
unsuccessful RNA isolation from control
synovium. 12
A previous report of CRH gene expression in
human colonic inflammation has been difficult
to reconcile with the authors' own evidence of
increased CRH staining in lamina propria cells
by immunohistochemistry.19 37 CRH mRNA
values detected by PCR analysis were higher in
normal than in ulcerative colitis mucosa37
whereas in situ hybridisation signals were
confined to scattered crypt epithelial cells and
did not differ among normal and inflamed
biopsy specimens.19 37 In our studies increased
ceacal CRH mRNA expression consistently
correlated with the development of inflam-
mation and irCRH in tissues as measured either
by RIA or immunohistochemistry. Moreover,
CRH mRNA values in the chronically inflamed
caecum at 29, 33, or 85 days were always high
compared with normal and HSA injected
control caecum (Fig 3). In most control tissues
CRH mRNA were undetectable by RT-PCR,
but occasionally we found low constitutive
CRH gene expression in normal and HSA
injected caecal control samples, consistent with
the constitutive CRH peptide values in control
tissues as measured by RIA (Fig 2).
The in vitro LPMC response to CRH
further supports the hypothesis that locally
produced CRH has an immunomodulatory
role in intestinal inflammation. In preliminary
studies we found that CRH regulates prolifer-
ation of splenocytes and LPMC as well as
cytokine production.40 The opposite effect of
CRH on spontaneous and mitogen induced
proliferation is ofunclear significance. Immune
cell responses to neuropeptide stimulation
depend on their activation state, for example,
intracellular second messenger levels. More-
over, ConA is a non-specific stimulus and may
not appropriately reproduce the in vivo
immunophysiological activation state of
LPMC in PG-APS induced enterocolitis.
These results however are consistent with other
studies describing stimulatory effects of CRH
on cytokine secretion, IL2 receptor expression,
reactive oxygen metabolite production by
macrophages, lymphocyte proliferation, and
natural killer cell activity.2228 Of relevance to
this study, the lymphoproliferative effect of
CRH is higher in B lymphocytes from gut
associated lymphoid tissue than in peripheral B
cells.27 Only a few reports indicate suppressive
effects of CRH on IL6 secretion and mitogen
induced antibody production.4' 42 These
findings in conjunction with studies showing
CRH synthesis by immune cells,434A4 high
affinity receptors for CRH on macrophages, T
and B lymphocytes,45A48 and autoreactive T cell
responses against CRH,47 support the concept
of a local immunomodulatory role for CRH in
inflammation.
In summary, our data show increase-d
intestinal CRH mRNA expression and tissue
concentrations in chronic experimental colitis
suggesting a role for CRH in intestinal inflam-
mation. More detailed in vitro studies with
isolated mucosal immune cells will provide
further insight into the immunostimulatory
activities of locally produced CRH and its
contribution to chronic disease in genetically
susceptible hosts.
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